Not yet recruiting
Acute myeloid leukaemia
Not yet recruitingA Phase 1/2 study of CHM-029 alone and in combination drug regimen in adults with newly diagnosed, relapsed or refractory Acute Myeloid Leukemia
Registered drugNo placebo
A Phase 1/2 study of CHM-029 alone and in combination drug regimen in adults with newly diagnosed, relapsed or refractory Acute Myeloid Leukemia
Registered drugNo placebo
- Disease:Acute myeloid leukaemia
- Substances:AzacitidineCytarabine+3
Countries:
France
France- Participants:18–64 years · 65+ years
- Substances:Azacitidine
- Sponsor:Charm Therapeutics Limited




